News & Updates

Full anticoagulation dosing confers survival advantage in hospitalized COVID-19 patients
Full anticoagulation dosing confers survival advantage in hospitalized COVID-19 patients
23 Mar 2023 byJairia Dela Cruz

A full, therapeutic dosing of anticoagulation flops for reducing the incidence of overall combined outcomes in noncritically ill patients hospitalized with COVID-19 as compared with prophylactic dosing, although there is a signal of benefit for mortality and disease progression with the therapeutic dosing, as shown in the FREEDOM COVID trial presented at ACC.23/WCC.

Full anticoagulation dosing confers survival advantage in hospitalized COVID-19 patients
23 Mar 2023
5-ASA maintenance therapy of little help in patients with newly diagnosed CD
5-ASA maintenance therapy of little help in patients with newly diagnosed CD
23 Mar 2023
Response to therapy higher in clinical trial than real-world RCC patients
Response to therapy higher in clinical trial than real-world RCC patients
22 Mar 2023

Among patients with metastatic renal cell carcinoma (RCC) who have received first-line therapies, complete response rates are lower in the real-world population than in the clinical trial population, reports a recent study. Complete response predicts a favourable overall survival.

Response to therapy higher in clinical trial than real-world RCC patients
22 Mar 2023